Sanne E. Franck
Rotterdam, ZH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Digital quantification of somatostatin receptor subtype 2a immunostaining: a validation study.
Journal: European journal of endocrinology
Published: April 27, 2022
Sustained intrinsic WNT and BMP4 activation impairs hESC differentiation to definitive endoderm and drives the cells towards extra-embryonic mesoderm.
Journal: Scientific reports
Published: May 11, 2020
Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 Expression.
Journal: The Journal of clinical endocrinology and metabolism
Published: July 12, 2018
The role of the reprogramming method and pluripotency state in gamete differentiation from patient-specific human pluripotent stem cells.
Journal: Molecular human reproduction
Published: October 06, 2017
In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas.
Journal: The Journal of clinical endocrinology and metabolism
Published: January 14, 2017
A multivariable prediction model for pegvisomant dosing: monotherapy and in combination with long-acting somatostatin analogues.
Journal: European journal of endocrinology
Published: November 22, 2016
The Effect of the Exon-3-Deleted Growth Hormone Receptor on Pegvisomant-Treated Acromegaly: A Systematic Review and Meta-Analysis.
Journal: Neuroendocrinology
Published: April 12, 2016
Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.
Journal: Neuroendocrinology
Published: February 03, 2016
Combined treatment of somatostatin analogues with pegvisomant in acromegaly.
Journal: Endocrine
Published: September 01, 2015
Pegvisomant in combination with long-acting somatostatin analogues in acromegaly: the role of the GH receptor deletion of exon 3.
Journal: European journal of endocrinology
Published: May 26, 2015
Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly.
Journal: The Journal of clinical endocrinology and metabolism
Published: June 18, 2014
Showing 1-12 of 12
Last Updated: 09/26/2026